Acompanhe as Notícias da Recifes

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become t

Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the immune system in preclinical mouse studies. Combined with immunotherapy, the treatment produced complete remissions in multiple mice, raising hopes for a powe